Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features : integrated analysis of two phase 3 studies - Burger, Jan A (Department of Leukemia. University of Texas MD Anderson Cancer Center) ; Robak, Tadeusz (Medical University of Lodz. Copernicus Memorial Hospital) ; Demirkan, Fatih (Dokuz Eylul University) ; Bairey, Osnat (Rabin Medical Center) ; Moreno, Carolina (Institut d'Investigació Biomèdica Sant Pau) ; Simpson, D. (BeiGene) ; Munir, Talha (Department of Haematology. St. James's Hospital) ; Stevens, D.A. (Norton Cancer Institute) ; Dai, S. (Pharmacyclics LLC. an AbbVie Company) ; Cheung, Leo W. K (Pharmacyclics LLC. an AbbVie Company) ; Kwei, Kevin (Pharmacyclics LLC. an AbbVie Company) ; Lal, Indu (Pharmacyclics LLC. an AbbVie Company) ; Hsu, E. (Pharmacyclics LLC. an AbbVie Company) ; Kipps, Thomas J (University of California San Diego. Moores Cancer Center) ; Tedeschi, A. (ASST Grande Ospedale Metropolitano Niguarda)